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S
ince the first AHA Science Advisory “Fish Consumption,
Fish Oil, Lipids, and Coronary Heart Disease,”1 impor-
tant new findings, including evidence from randomized
controlled trials (RCTs), have been reported about the bene-
ficial effects of omega-3 (or n-3) fatty acids on cardiovascular
disease (CVD) in patients with preexisting CVD as well as in
healthy individuals.2 New information about how omega-3
fatty acids affect cardiac function (including antiarrhythmic
effects), hemodynamics (cardiac mechanics), and arterial
endothelial function have helped clarify potential mecha-
nisms of action. The present Statement will address distinc-
tions between plant-derived (-linolenic acid, C18:3n-3) and
marine-derived (eicosapentaenoic acid, C20:5n-3 [EPA] and
docosahexaenoic acid, C22:6n-3 [DHA]) omega-3 fatty ac-
ids. (Unless otherwise noted, the term omega-3 fatty acids
will refer to the latter.) Evidence from epidemiological
studies and RCTs will be reviewed, and recommendations
reflecting the current state of knowledge will be made with
regard to both fish consumption and omega-3 fatty acid
(plant- and marine-derived) supplementation. This will be
done in the context of recent guidance issued by the US
Environmental Protection Agency and the Food and Drug
Administration (FDA) about the presence of environmental
contaminants in certain species of fish.
Epidemiological and Observational Studies
Coronary Heart Disease
As reviewed by Stone,1 three prospective epidemiological
studies within populations reported that men who ate at least
some fish weekly had a lower coronary heart disease (CHD)
mortality rate than that of men who ate none.3–6 More recent
evidence that fish consumption favorably affects CHD mor-
tality, especially nonsudden death from myocardial infarction
(MI), has been reported in a 30-year follow-up of the Chicago
Western Electric Study.7 Men who consumed 35 g or more of
fish daily compared with those who consumed none had a
relative risk of death from CHD of 0.62 and a relative risk of
nonsudden death from MI of 0.33. In an ecological study
conducted by Zhang et al,8 fish consumption was associated
with a reduced risk from all-cause, ischemic heart disease and
stroke mortality across 36 countries. In addition, in a study of
Japanese living in Japan or Brazil, Mizushima et al9 reported
a dose-response relationship between the frequency of
weekly fish intake and reduced CVD risk factors (eg, obesity,
hypertension, glycohemoglobin, ST-T segment change on the
ECG). Until recently, little information was available about
the effects of fish and omega-3 fatty acids and risk of CHD in
women. A recent study conducted with women in the Nurses’
Health Study10 reported an inverse association between fish
intake and omega-3 fatty acids and CHD death. Compared
with women who rarely ate fish (less than once per month),
the risk for CHD death was 21%, 29%, 31%, and 34% lower
for fish consumption 1 to 3 times per month, once per week,
2 to 4 times per week, and 5 times per week, respectively
(P for trend0.001). Comparing the extreme quintiles of fish
intake, the reduction in risk for CHD deaths seemed to be
stronger for CHD death than for nonfatal MI (RR 0.55 versus
0.73).
Some studies have not reported a beneficial association of
fish consumption and CHD mortality. In the Health Profes-
sionals’ Follow-up Study,11 no significant association was
observed between fish intake (and omega-3 fatty acids) and
risk of any CHD (ie, fatal coronary disease including sudden
death, nonfatal MI, coronary artery bypass grafting, or angio-
plasty). Likewise, the US Physicians’ Health Study did not
show an association between fish consumption (or omega-3
fatty acid intake) and reduced risk of total MI, nonsudden
cardiac death, or total cardiovascular mortality.12 In contrast,
however, fish consumption was related to a reduced risk of
total mortality. The lack of an association between fish intake
and CHD incidence and mortality also was reported from an
analysis of the Seven Countries data and the EURAMIC
(European Multicenter Case-Control Study on Antioxidants,
Myocardial Infarction and Breast Cancer) Study.13,14 In the
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between fish consumption and 25-year mortality from CHD
across several populations was observed,13 when the con-
founding effects of saturated fatty acids, flavonoids, and
smoking were considered, the association was not significant.
In the EURAMIC Study, a large international case-control
study, no evidence of a protective effect of adipose tissue
DHA (a measure of long-term fish consumption) on the risk
of developing MI was seen.14
Some investigators have speculated that the conflicting
data from the epidemiological studies reflect differences in
definitions of sudden death and the residual confounding of
reference groups that had a less healthy lifestyle,15 variability
in the end points studied, experimental design or how fish
intake was estimated, different study populations,16 and the
possible confounding effect of an increase in hemorrhagic
stroke. Albert et al12 proposed that their lack of an association
may have been due to the small fraction of their study
population (3.1%) reporting little to no fish consumption.
Only studies including sizable non–fish-eating populations
have reported an inverse association between fish consump-
tion and coronary mortality. In the EURAMIC Study, only
survivors of MI were evaluated, and it is conceivable that
individuals who did not survive ate less fish. Another expla-
nation, based on a rigorous analysis of 11 prospective cohort
studies, is that the protective effect of fish consumption
relates to the CHD risk status of the population studied17; this
analysis concluded that fish consumption reduced CHD
mortality (RR0.4 to 0.6) in high-risk but not low-risk
populations. Another consideration relates to the type of fish
consumed (ie, fatty versus lean fish). Oomen et al18 reported
a lower CHD mortality (RR0.66) in populations that
consumed fatty fish but not lean fish.
Finally, another explanation for the discordant results of
epidemiological studies pertains to the hypothesized adverse
effects of methylmercury, an environmental contaminant
found in certain fish that may diminish the health benefits of
omega-3 fatty acids.19 Recent studies have produced conflict-
ing results with regard to the effects of methylmercury on
CHD risk.20,21 Thus, the extent to which methylmercury in
fish may mask the beneficial effects of omega-3 fatty acids
requires further study.
Fish consumption has been shown to be related to reduced
sudden cardiac death. In a population-based, nested, case-
control study, a strong negative relationship was reported
between fish intake and risk for sudden death (ie, 5.5 g of
omega-3 fatty acids per month, equivalent to two fatty fish
meals per week, was associated with a 50% reduced risk of
primary cardiac arrest).22 In the US Physicians’ Health Study,
men who consumed fish at least once weekly had a relative
risk of sudden death of 0.48 (P0.04) versus men who
consumed fish less than once per month.12 A recent report
from the Physicians’ Health Study23 reported an inverse
relationship between blood levels of long-chain omega-3
fatty acids and risk of sudden death in men without a history
of CVD. The relative risk of sudden death was significantly
lower among men with levels in the third quartile (RR0.28)
and the fourth quartile (RR0.19) compared with men whose
blood levels were in the first quartile.
Further evidence for a protective effect of omega-3 fatty
acids comes from two recent studies by Landmark et al24,25
who reported that chronic intake of fish or fish oil was
associated with a reduction in infarct size as estimated by the
frequency of Q-wave infarcts and by peak creatine kinase and
lactate dehydrogenase activities after MI. In contrast to all the
studies demonstrating a beneficial association, the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study found
that estimated omega-3 fatty acid intake from fish was
associated with a trend toward increased relative risk of
coronary death after adjustment for trans, saturated, and
cis-monounsaturated fatty acids.26
A growing body of evidence from recent epidemiological
studies indicates that -linolenic acid is associated with a
lower risk of MI and fatal ischemic heart disease in women
and in men. In the EURAMIC Study, Guallar et al14 com-
pared the highest quintile of adipose tissue -linolenic acid to
the lowest and found a relative risk for MI of 0.42 (P for
trend0.02). This became nonsignificant after adjusting for
classic risk factors (primarily smoking). Using a food-
frequency questionnaire from a 10-year follow-up of the
Nurses’ Health Study, and after controlling for standard
coronary risk factors, Hu et al27 reported a dose-response
relationship between -linolenic acid intake and relative risk
of fatal ischemic heart disease, which was reduced by 45% in
the highest quintile (P for trend0.01). Similar findings were
reported with the same methodology in the all-male Health
Professionals’ Study, in which a 1% increase in -linolenic
acid intake was associated with a 0.41 relative risk for acute
MI (P for trend0.01).28 Lowest-quintile intakes of -linole-
nic acid in these latter two trials were 0.7 to 0.8 g/d, and
highest quintile intakes, 1.4 to 1.5 g/d. In the National Heart,
Lung, and Blood Institute Family Heart Study, a cross-
sectional study with 4584 participants, -linolenic acid was
inversely related to coronary artery disease.29 The prevalence
odds ratio of coronary artery disease was reduced 40% for
men in the top three quintiles of -linolenic acid intake and
50% to 70% for women. In contrast, in the Zutphen Elderly
Study, a prospective epidemiological study with 667 men,
ages 64 to 84 years, there was no beneficial effect of
-linolenic acid intake on risk of 10-year coronary artery
disease incidence.30 In the latter study, however, these nega-
tive results have been explained by the association between
-linolenic acid and trans-fatty acid intake,30 as well as by
limitations in the collection of the dietary data.31 Despite this
latter study, a growing epidemiological database demon-
strates a protective effect of -linolenic acid on coronary
disease. Nonetheless, intervention studies are needed to
establish a causal relationship between -linolenic acid intake
and coronary disease.
Stroke
Compared with the literature describing the effects of
omega-3 fatty acids on CHD, relatively little information
about the association of omega-3 fatty acids and cerebral
infarctions (stroke) is available. Several epidemiological
studies have examined the relationship between fish intake
and stroke incidence. In the Zutphen Study, the unadjusted
hazard ratio of men who consumed an average of 20 g/d of
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less.32 Likewise, in the National Health and Nutrition Exam-
ination Survey (NHANES) Epidemiologic Follow-up Study,
white females who consumed fish more than once per week
had an age-adjusted stroke incidence that was only half that of
women who reported not consuming fish.33 A similar protec-
tive effect was seen in both black women and men but not in
white men. A trend (P0.06) toward reduced risk for stroke
with increasing reported fish consumption was also reported
in the Nurses’ Health Study.34 In contrast, both the Chicago
Western Electric Study35 and the Physicians’ Health Study36
failed to find any relationship between reported fish intake
and reduced stroke risk.
According to the serum fatty acid profiles of subjects in the
Multiple Risk Factor Intervention Trial, -linolenic acid was
negatively associated with stroke incidence.37 In both the
Lyon Diet Heart Study38 (testing a Mediterranean-style diet
enriched with -linolenic acid) and the GISSI-Prevention
Study39 (testing the effects of 850 mg of supplemental
omega-3 fatty acids), there was no significant effect on the
incidence of stroke.
The evidence to date is primarily for total stroke risk, and
associations could differ if the data were analyzed for
type-specific stroke incidence. For example, evidence exists
for an inverse relationship between small intakes of fish (1
portion per week) and ischemic stroke32 and for a possible
increased risk for hemorrhagic stroke with “Eskimo” intakes
of omega-3 fatty acids.40 Thus, as Zhang et al8 have noted,
linking fish consumption with total stroke risk is likely to
underestimate the strength of the real associations between
fish consumption and type-specific stroke risk.
Randomized Controlled Trials
At the time of the first Advisory, the only RCT of omega-3
fatty acids in secondary prevention of CHD was the Diet And
Reinfarction Trial (DART), which reported a 29% reduction
in all-cause mortality over a 2-year period in male MI
survivors advised to increase their intake of oily fish (200 to
400 g of fatty fish per week, which provided an additional
500 to 800 mg/d of omega-3 fatty acids).41 The greatest
benefit was seen in fatal MIs, and this observation led to the
hypothesis that omega-3 fatty acids might protect the myo-
cardium against the adverse sequela of acute ischemic stress.
A post hoc analysis of patients receiving fish oil capsules
(900 mg/d of EPADHA) in DART suggested that the
protective effect was attributable to omega-3 fatty acids.42
The first of three recent RCTs designed to detect the effects
of supplemental EPA and DHA on clinical events was
reported by Singh et al.43 Patients admitted to the hospital
with suspected acute MIs were randomized to either fish oil
capsules (containing 1.8 g/d of EPADHA), mustard oil (20
g/d providing 2.9 g -linolenic acid), or placebo. After one
year, total cardiac events were 25% and 28% in the fish oil
and mustard oil groups, respectively, versus 35% in the
placebo group (P0.01). As in the DART, nonfatal MIs were
significantly lower in the fish oil and mustard oil groups.
The largest prospective RCT to test the efficacy of
omega-3 fatty acids for secondary prevention of CHD is the
GISSI-Prevention Study.39 In this study, 11 324 patients with
preexisting CHD (who were receiving conventional cardiac
pharmacotherapy) were randomized to either 300 mg of
vitamin E, 850 mg of omega-3 fatty acid ethyl esters (as EPA
and DHA), both, or neither. After 3.5 years of follow-up, the
group given the omega-3 fatty acids alone experienced a 15%
reduction in the primary end point of death, nonfatal MI, and
nonfatal stroke (P0.02). There was a 20% reduction in
all-cause mortality (P0.01) and a 45% reduction in sudden
death (P0.001) compared with the control group; vitamin E
provided no additional benefit. Triglycerides decreased by
4% and LDL cholesterol levels increased by 2.5% after six
months in the omega-3 fatty acid treatment groups compared
with controls. This trial, although very large and carried out
in a relatively “usual-care” setting, was not placebo con-
trolled, and dropout rates were high (25%). A follow-up
study44 assessed the time-course of the benefit of omega-3
fatty acids on mortality in subjects in the GISSI Study and
found that survival curves diverged early after randomization.
Total mortality was significantly lowered after 3 months of
treatment (RR0.59), and by 4 months, risk of sudden death
was reduced (RR0.47).
In contrast to the growing body of evidence supporting a
protective effect of omega-3 fatty acids in secondary preven-
tion, a recent study reported no effect of 3.5 g/d of
DHAEPA versus corn oil on cardiac events in post-MI
patients (n300) after 1.5 years of intervention.45 The au-
thors speculated that the lack of an omega-3 fatty acid effect
may have been due to the high habitual fish intake in western
Norway, which could have afforded maximal protection
beyond which no additional effects would be expected. Thus,
further research is needed to confirm and further define the
role of omega-3 fatty acid supplements for secondary preven-
tion of coronary disease.
The first study to explore the effects of omega-3 fatty acids
on angiographic progression rates provided 59 patients either
6 g/d of omega-3 fatty acids or olive oil for 2 years.46 No
benefit was observed. More recently, a larger trial using
lower and more practical intakes of omega-3 fatty acids has
been reported.47 Patients presenting for coronary angiography
(n223) were randomized to either placebo or omega-3 fatty
acids (3 g/d for 3 months followed by 1.5 g/d for 21 months).
The latter group exhibited significantly (P0.04) less pro-
gression, more regression, and a trend toward fewer clinical
events (7 versus 2, P0.1). Finally, Eritsland et al48 reported
that in 610 patients undergoing coronary artery bypass
grafting, the provision of 3.4 g of omega-3 fatty acid ethyl
esters lowered vein graft occlusion rates from 33% (control)
to 27% (P0.03).
Several randomized trials of fish oil were conducted over
the past 10 years to test the hypothesis that omega-3 fatty
acids could prevent restenosis after percutaneous translumi-
nal coronary angioplasty. Although a meta-analysis of seven
early trials concluded that supplementation was beneficial,49
more recent trials (with large study populations given 5 to 7
g/d of omega-3 fatty acids) have not supported this conclu-
sion.50,51 Most investigators have concluded that further trials
are not warranted.
The question of the efficacy of -linolenic acid in CHD
prevention has been examined in four trials. The Indian
Kris-Etherton et al Fish Consumption and CVD 2749
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significant decrease in total cardiac events in the group
assigned to mustard seed oil. The Lyon Heart Trial was a
secondary prevention trial designed to test whether a
Mediterranean-type diet (including increased amounts of
-linolenic acid) would reduce reoccurrence rates of cardiac
events compared with a prudent Western diet.38,52 Marked
reductions were seen in cardiac death and nonfatal MI, major
secondary end points, and minor events. The difference in
intakes of -linolenic acid between groups was 0.5 versus 1.5
g/d. It is impossible, however, to ascribe the benefit unam-
biguously to -linolenic acid because many other dietary
variables were present: Saturated fat and cholesterol de-
creased and monounsaturated fat increased, as did the con-
sumption of fruits and vegetables.
Although the Indian Experiment of Infarct Survival43 and
the Lyon Heart Trial38 provide clinical trial evidence in
support of a beneficial effect of -linolenic acid, the Norwe-
gian Vegetable Oil Experiment53 and the Mediterranean
Alpha-Linolenic Enriched Groningen Dietary Intervention
(MARGARIN) Study54 do not. The Norwegian Vegetable Oil
Experiment was a double-blind RCT in which 13 000 men
ages 50 to 59 with no history of MI were randomized to
consume 5.5 g/d of -linolenic acid (from 10 mL of linseed
oil) or 10 mL of sunflower seed oil for one year. There were
27 cases of new CHD or sudden death in each group, and 40
versus 43 deaths from any cause in the control versus the
linseed oil groups. In the MARGARIN Study, free-living
subjects (n124 men and 158 women) with multiple CVD
risk factors were provided with margarines high in either
-linolenic acid or linoleic acid and followed up for 2 years.54
According to effects on CVD risk factors, the 10-year
estimated ischemic heart disease risk decreased similarly in
both groups (2.1% and 2.5%, respectively). Of note, however,
was a trend toward fewer CVD events in the -linolenic acid
group (1.8% versus 5.7%, P0.20). It is important that
additional studies be conducted to clarify the role of -lin-
olenic acid in reducing CHD risk.
In aggregate, available RCTs show a beneficial effect of
dietary and supplemental omega-3 fatty acids, including both
EPADHA and -linolenic acid, on CHD. This has been
summarized in a recent meta-analysis of 11 RCTs with 7951
patients in the intervention groups.55 In this meta-analysis, the
risk ratio of nonfatal MI was 0.8, for fatal MI it was 0.7, and
for sudden death (in 5 trials) it was 0.7.
Possible Mechanisms
The mechanisms responsible for the observed effects of
omega-3 fatty acids on cardiovascular health are not known
with confidence, especially at the low intakes utilized in the
DART and GISSI Prevention Study. Those possibly involved
are summarized in Table 1.56
Triglycerides
The hypotriglyceridemic effects of omega-3 fatty acids from
fish oils are well established. In a comprehensive review of
human studies, Harris57 reported that 4 g/d of omega-3 fatty
acids from fish oil decreased serum triglyceride concentra-
tions by 25% to 30%, with accompanying increases in LDL
cholesterol of 5% to 10% and in HDL cholesterol of 1% to
3%. A dose-response relationship exists between omega-3
fatty acid intake and triglyceride lowering.57 Postprandial
triglyceridemia is especially sensitive to chronic omega-3
fatty acid consumption,58,59 with quite small intakes (2 g/d)
producing significant reductions.60 The plasma lipid and
lipoprotein responses to fish oil are comparable in diabetic
and nondiabetic subjects.61 In addition, a recent meta-analysis
of 26 trials of subjects with type 1 or type 2 diabetes mellitus
reported no effects of fish oil on hemoglobin A1c,62 although
fasting blood glucose levels rose slightly in the latter group.
Fish oil can have a therapeutic role in the treatment of
marked hypertriglyceridemia (750 mg/dL). Effective doses
of omega-3 fatty acids range from 3 to 5 g/d, which can only
be obtained consistently by supplementation. At present, it
seems that both EPA and DHA have triglyceride-lowering
properties.63 Patients taking 3go fE P A DHA from
supplements should do so only under a physician’s care
because the FDA has noted that an intake in excess of this
level could result in excessive bleeding in some individuals.64
In contrast, cardioprotective intakes seem to be considerably
lower (1 g/d), have almost no potential for adverse effects,
and can be achieved by diet.
Blood Pressure
Omega-3 fatty acids seem to have a small, dose-dependent,
hypotensive effect, the extent of which seems to be dependent
on the degree of hypertension.65 In a meta-analysis, Morris et
al66 found a significant reduction in blood pressure of
3.4/2.0 mm Hg in studies with hypertensive subjects who
consumed 5.6 g/d of omega-3 fatty acids. Likewise, Appel et
al67 found that blood pressure was decreased 5.5/
3.5 mm Hg in trials of untreated hypertensives given 3
g/d of omega-3 fatty acids. DHA seems to be more effective
than EPA in lowering blood pressure.68 Still, in view of the
high dose required to lower blood pressure and the proven
efficacy of other nutritional factors and of antihypertensive
medications, an increased intake of omega-3 fatty acids has a
limited role in the management of hypertension.
Thrombosis and Hemostasis
Omega-3 fatty acids decrease platelet aggregation,69,70 result-
ing in a modest prolongation of bleeding times (reviewed by
Knapp71). Some evidence indicates that fish oil supplemen-
TABLE 1. Potential Mechanisms by Which Omega-3 Fatty
Acids May Reduce Risk for Cardiovascular Disease
Reduce susceptibility of the heart to ventricular arrhythmia
Antithrombogenic
Hypotriglyceridemic (fasting and postprandial)
Retard growth of atherosclerotic plaque
Reduce adhesion molecule expression
Reduce platelet-derived growth factor
Antiinflammatory
Promote nitric oxide-induced endothelial relaxation
Mildly hypotensive
Adapted from Connor.
56
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acid intake has been negatively associated with levels of
fibrinogen, Factor VIII, and von Willebrand factor,73 more
recent evidence from the Coronary Artery Risk Development
In young Adults (CARDIA) study found no significant
associations between customary intakes of fish (4 to 39 g/d)
and omega-3 fatty acids (0.9 to 4.1 g/d) and these coagulation
factors.74 Marckmann et al75 also found no effect of omega-3
fatty acids (0.9 g/d) on levels of Factor VII, fibrinogen,
endogenous fibrinolysis, -thromboglobulin, and von Wille-
brand factor. In contrast, a recent study reported that coronary
patients taking 5.1 g/d of omega-3 fatty acids for 6 months
experienced a reduction in von Willebrand factor (128%
versus 147% for controls) and thrombomodulin (25 versus 33
ng/mL).76 Although it seems clear that omega-3 fatty acids
beneficially influence collagen-induced platelet aggregation
(thereby affecting hemostasis), their effects on thrombosis
remain unclear. There is little evidence to suggest that an
intake 3 g/d of omega-3 fatty acids would cause clinically
significant bleeding.
Arrhythmias
The possibility that omega-3 fatty acids (including -linole-
nic acid) may reduce risk for sudden cardiac death is based on
evidence from a prospective cohort study,12 a case-control
study,22 and four prospective dietary intervention tri-
als.38,39,41,43 Proposed mechanisms to explain these observa-
tions center not on lipid or blood pressure lowering or on
antithrombotic effects, but on a novel stabilizing effect of
omega-3 fatty acids on the myocardium itself. Evidence for a
direct effect of these fatty acids on the heart has come from
several observations. First, increased heart rate variability in
survivors of MI was associated with the consumption of one
fish meal per week77 or fish oil supplements (4.3 g/d of
omega-3 fatty acids).78 Increases in this parameter predict a
lower risk of mortality due to arrhythmic events in post-MI
patients. EPA and DHA also have been shown to reduce
resting heart rate and increase left ventricular filling capaci-
ty.79 Animal experiments and cell culture studies have shown
that fish oil has potent antiarrhythmic effects. For example,
studies with rats80 and dogs81,82 have shown that pretreatment
with omega-3 fatty acids reduced damage to cardiac tissue
and forestalled the development of ventricular dysrhythmias
when heart attacks were induced. Similar observations were
made in fish oil–fed cats that were protected from cerebral
damage after stroke induction.83 In vitro induction of
tachyarrhythmias in cultured neonatal rat ventricular myo-
cytes by various pharmacological agents (such as ouabain)
can be prevented or abolished by the addition of omega-3
fatty acids to the culture medium (reviewed by Kang and
Leaf84). This seems to be due to the ability of omega-3 fatty
acids to prevent calcium overload by maintaining the activity
of L-type calcium channels during periods of stress,85 and to
increase the activity of cardiac microsomal Ca
2/Mg
2-
ATPase.79 In addition, omega-3 fatty acids (including -lin-
olenic acid) are potent inhibitors of voltage-gated sodium
channels in cultured neonatal cardiac myocytes, which may
contribute to the reduction in arrhythmia.84
Other Biological Effects
Goode et al86 showed that acetylcholine-stimulated relaxation
of small arteries taken from hypercholesterolemic patients
was significantly improved after three months of supplemen-
tation with 3 g/d of EPADHA. Fish oil feeding has also
been shown to improve endothelial function (reviewed by
Chin and Dart87) and to increase arterial compliance.88 These
effects may be secondary to fish oil’s ability to enhance nitric
oxide production89 and may be the mechanism by which fish
oil elicits a small hypotensive effect.
Mechanisms to explain the antiatherogenic (inhibition of
new plaque development) effect of omega-3 fatty acids have
recently been proposed.48 For example, EPA and DHA seem
to alter the metabolism of adhesion molecules such as
vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and
intercellular adhesion molecule-1 (ICAM-1). Abe et al
(1998)90 reported a 9% reduction in soluble ICAM-1 and a
16% reduction in soluble E-selectin but not in soluble
VCAM-1 in hypertriglyceridemic subjects receiving 3.4 g/d
of highly purified omega-3 fatty acid ethyl esters for 7 to 12
months. There is also in vitro evidence that DHA reduces
endothelial expression of VCAM-1 and the expression of
E-selectin, ICAM-1, interleukin (IL)-6, and IL-8 in stimu-
lated cells.91,92 On the other hand, a study in male smokers
with hyperlipidemia showed that six weeks of omega-3 fatty
acid supplementation (4.8 g/d) increased soluble forms of
E-selectin and VCAM-1.93 A subsequent study in coronary
patients given supplemental omega-3 fatty acids (5.1 g/d for
6 months) found similar results.76 Fish oil also affects the
metabolism of inflammatory mediators like the interleukins
and tumor necrosis factor-,94 molecules also believed to play
a role in atherogenesis and plaque stability.95
Another potential antiatherogenic mechanism of omega-3
fatty acids is their interference with the arachidonic acid
cascade that generates a wide variety of eicosanoids (re-
viewed by Uauy et al96). EPA not only can replace arachi-
donic acid in phospholipid bilayers, but it is also a competi-
tive inhibitor of cyclooxygenase, reducing the production of
the 2-series prostaglandins, thromboxanes, and prostacyclins
and the 4-series leukotrienes. The 3- and 5-series (respective-
ly) produced from EPA are generally less biologically active.
DHA, although not a direct inhibitor of arachidonic acid
metabolism, nevertheless can inhibit platelet aggregation by
reducing the affinity of platelet TxA2/PGH2 receptor for its
ligand.97 The net effects of omega-3 fatty acids are thus to
reduce inflammatory processes, vasoconstriction, and platelet
aggregation, all known to be antiatherogenic.
Some studies have shown that omega-3 fatty acids may
increase the susceptibility of LDL to oxidation,98,99 whereas
others have not.100–102 It therefore remains to be established
whether LDL oxidative status in vivo is affected by omega-3
fatty acids and, if so, whether this has any adverse clinical
implications. Our current inability to identify and quantify in
vivo oxidative damage and to relate it to clinical outcomes
makes it difficult to draw firm conclusions about the impact
of omega-3 fatty acids on these processes.
Intake of Omega-3 Fatty Acids
The intake of total omega-3 fatty acids in the United States is
1.6 g/d (0.7% of energy intake).103 Of this, -linolenic
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from EPA and DHA. The major food sources of -linolenic
acid are vegetable oils, principally canola and soybean oils.
Other food sources that are rich in -linolenic acid (Table
2)104 include flaxseed (23 g/100 g) and English walnuts (7
g/100 g). Although some -linolenic acid is converted to the
longer-chain omega-3 fatty acids, the extent of this conver-
sion is modest and controversial. For example, Emken et al105
reported a 15% conversion, whereas Pawlosky et al106 found
0.2%; both reported that the conversion to DHA was much
less than that to EPA. Fish are the major food source of EPA
and DHA (Table 3).104 All fish contain EPA and DHA;
however, the quantities vary among species and within a
species according to environmental variables such as diet and
whether fish are wild or farm-raised. Farm-raised catfish tend
to have less EPA and DHA than do wild catfish, whereas
farm-raised salmon and trout contain similar amounts versus
their wild counterparts.
A number of countries (Canada, Sweden, United Kingdom,
Australia, Japan) as well as the World Health Organization
and North Atlantic Treaty Organisation have made formal
population-based dietary recommendations for omega-3 fatty
acids. Typical recommendations are 0.3 to 0.5 g/d of
EPADHA and 0.8 to 1.1 g/d of -linolenic acid. Recently,
the Food and Nutrition Board, Institute of Medicine, and The
National Academies, in collaboration with Health Canada,
released the Dietary Reference Intakes for Energy and Ma-
cronutrients.107 The Acceptable Macronutrient Distribution
Range (AMDR) for -linolenic acid is estimated to be 0.6%
to 1.2% of energy, or 1.3 to 2.7 g/d on the basis of a
2000-calorie diet. This is 10 times the current intake of
EPADHA. The lower boundary of the range is based on an
Adequate Intake set for -linolenic acid, which represents
median intake levels that prevent an essential fatty acid
deficiency. The upper boundary corresponds to the highest
-linolenic acid intakes from foods consumed by individuals
in the United States and Canada. Thus, the intent of the
AMDR range for omega-3 fatty acids is to provide guidance
for healthy people, not to prevent chronic disease. These
recommendations can easily be met by following the AHA
Dietary Guidelines to consume two fish meals per week, with
an emphasis on fatty fish (ie, salmon, herring, and mackerel),
and by using liquid vegetable oils containing -linolenic acid.
Commercially prepared fried fish (eg, from restaurants and
fast food establishments, as well as many frozen,
convenience-type fried fish products) should be avoided
because they are low in omega-3 and high in trans-fatty acids.
Patients with CHD should be encouraged to increase their
consumption of EPA and DHA to 1 g/d, which is the dose
used in the GISSI-Prevention Study. Table 3 presents
omega-3 fatty acid content of various fish and supplements as
well as the amount required each day to provide 1 g/d of
EPADHA. Although this level of EPA and DHA intake
potentially can be attained through fish consumption, the
requisite amount of fish intake may be difficult to achieve and
sustain over the long term. For those individuals who do not
eat fish, have limited access to a variety of fish, or cannot
afford to purchase fish, a fish oil supplement may be
considered. Depending on the preparation, up to three 1-g fish
oil capsules per day will be necessary to provide 1 g/d of
omega-3 fatty acids. The most common fish oil capsules in
the United States today provide 180 mg of EPA and 120 mg
DHA per capsule. It is important that consumers read the
nutrition label to determine EPA and DHA levels in the fish
oil capsule.
Safety of Omega-3 Fatty Acids
Omega-3 fatty acids have been a part of the human diet for
millennia. It has been estimated that the ratio of omega-6 to
omega-3 fatty acids in the diet of early humans was 1:1.108
The ratio in the United States today has risen to 10:1
because of the combination of reduced omega-3 fatty acid
intake and the widespread use of vegetable oils rich in
linoleic acid.103 Because of the well-known competition
between the omega-6 linoleate and the omega-3 -linolenate
for metabolic conversion to longer-chain, physiologically
active metabolites, reducing the former while increasing the
latter (or simply increasing the latter) is a strategy for
increasing tissue levels of omega-3 fatty acids.109 Another
obvious strategy is to simply consume more EPA and DHA,
an approach that minimizes the significance of the ratio.
Since the first omega-3 fatty acid advisory,1 the FDA has
ruled that intakes of up to 3 g/d of marine omega-3 fatty acids
are GRAS (Generally Recognized As Safe) for inclusion in
the diet.110 This ruling included specific consideration of the
reported effects of omega-3 fatty acids on glycemic control in
patients with diabetes, on bleeding tendencies, and on LDL
cholesterol. Moreover, the FDA recently has approved a
qualified health claim for EPA and DHA omega-3 fatty acids
in dietary supplements.64
Although the safety of low intakes does not seem to be an
issue, and supplements are essentially mercury free, some
side effects of omega-3 fatty acid supplementation do occur
(Table 4).111 Perhaps the most common is a fishy aftertaste. In
the GISSI Prevention study, which provided 0.85 g of
omega-3 fatty acids per day for 3.5 years, 3.8% of patients
discontinued taking their supplements (compared with 2.1%
for the vitamin E group). Gastrointestinal disturbances and
nausea were the most commonly reported side effects, with
4.9% and 1.4% reported, respectively, compared with 2.9%
and 0.4% in the vitamin E group. When 12 capsules contain-
TABLE 2. -Linolenic Acid Content of Selected Vegetable Oils,
Nuts, and Seeds
-Linolenic Acid
Content, g/tbsp
Olive oil 0.1
Walnuts, English 0.7
Soybean oil 0.9
Canola oil 1.3
Walnut oil 1.4
Flaxseeds 2.2
Flaxseed (linseed) oil 8.5
Adapted from USDA Nutrient Data Laboratory.
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 by on June 5, 2007  circ.ahajournals.org Downloaded from TABLE 3. Amounts of EPADHA in Fish and Fish Oils and the Amount of Fish
Consumption Required to Provide 1go fE P A DHA per Day
EPADHA Content,
g/3-oz Serving Fish
(Edible Portion) or g/g Oil
Amount Required to Provide
1go fE P A DHA
per Day, oz (Fish) or g (Oil)
Fish
Tuna
Light, canned in water, drained 0.26 12
White, canned in water, drained 0.73 4
Fresh 0.24–1.28 2.5–12
Sardines 0.98–1.70 2–3
Salmon
Chum 0.68 4.5
Sockeye 0.68 4.5
Pink 1.09 2.5
Chinook 1.48 2
Atlantic, farmed 1.09–1.83 1.5–2.5
Atlantic, wild 0.9–1.56 2–3.5
Mackerel 0.34–1.57 2–8.5
Herring
Pacific 1.81 1.5
Atlantic 1.71 2
Trout, rainbow
Farmed 0.98 3
Wild 0.84 3.5
Halibut 0.4–1.0 3–7.5
Cod
Pacific 0.13 23
Atlantic 0.24 12.5
Haddock 0.2 15
Catfish
Farmed 0.15 20
Wild 0.2 15
Flounder/Sole 0.42 7
Oyster
Pacific 1.17 2.5
Eastern 0.47 6.5
Farmed 0.37 8
Lobster 0.07–0.41 7.5–42.5
Crab, Alaskan King 0.35 8.5
Shrimp, mixed species 0.27 11
Clam 0.24 12.5
Scallop 0.17 17.5
Capsules
Cod liver oil* 0.19 5
Standard fish body oil 0.30 3
Omega-3 fatty acid concentrate 0.50 2
Omacor (Pronova Biocare)† 0.85 1
Data from the USDA Nutrient Data Laboratory.
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The intakes of fish given above are very rough estimates because oil content can vary markedly
(300%) with species, season, diet, and packaging and cooking methods.
*This intake of cod liver oil would provide approximately the Recommended Dietary Allowance of
vitamins A and D.
†Not currently available in the United States.
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years, three patients dropped from the study claiming intol-
erance to the capsules.46 In a 6-month trial providing 275
patients with 6.9 g of EPADHA in 10 capsules daily, there
was no difference between the fish oil and corn oil control
groups for any adverse event.112 Gastrointestinal upset was
reported by 8% of the latter and 7% of the former. Finally,
although refined and concentrated omega-3 fatty acid prod-
ucts contain virtually no methylmercury and are very low in
organochloride contaminants,113 less well-controlled prepara-
tions can contain appreciable amounts.114
Safety of Fish
Some species of fish may contain significant levels of
methylmercury, polychlorinated biphenyls (PCBs), dioxins,
and other environmental contaminants. These substances are
present at low levels in fresh waters and oceans, and they
bioconcentrate in the aquatic food chain such that levels are
generally highest in older, larger, predatory fish and marine
mammals.
Fish and seafood are a major source of human exposure to
these contaminants. PCBs and methylmercury have long
half-lives in the body and can accumulate in people who
consume contaminated fish on a frequent basis. Consumers
can reduce their exposure to PCBs by removing the skin and
fat from these fish before cooking them; however, because
methylmercury is distributed throughout the muscle, skinning
and trimming does not significantly reduce mercury concen-
trations in filets.
The responsibility for regulating the quality of the fish for
human consumption is shared by the states and two federal
agencies. The Environmental Protection Agency regulates
sport-caught fish, whereas the FDA regulates all commercial
fish—including farm-raised, imported, and marine fish. The
Environmental Protection Agency’s 2000 National Listing of
Fish and Wildlife Advisories may be found on the Environ-
mental Protection Agency web site.115 The Environmental
Protection Agency advises women who are pregnant or may
become pregnant and nursing mothers to limit their consump-
tion of sport-caught fish to one 6-ounce meal per week.116
The Environmental Protection Agency also recommends that
young children consume 2 ounces of sport-caught fish per
week. The FDA recommends that women who are pregnant
or nursing and young children eliminate shark, swordfish,
king mackerel in the mackerel family, and tilefish (also
referred to as golden bass or golden snapper) from their diets
completely and limit their consumption of other fish to 12
ounces per week (3 to 4 servings/wk) to minimize exposure
to methylmercury.117 The FDA has concluded that persons
other than pregnant women and women who may become
pregnant can consume up to 7 ounces per week of fish with
methylmercury levels around 1 ppm (eg, shark, swordfish,
king mackerel, tilefish) and 14 ounces per week of fish with
mercury levels averaging 0.5 ppm (eg, fresh tuna, orange
roughy, marlin, red snapper).118 In July 2002, an FDA
Scientific Committee advised the FDA to conduct a more
detailed analysis of the contribution of methylmercury from
tuna (with emphasis on large tuna consumed as steaks rather
than canned tuna) to total methylmercury levels in women
and children. Although more data are needed, information
currently available about the methylmercury content of se-
lected fish can be found on the FDA web site.119
In summary, consumers need to be aware of both the
benefits and risks of fish consumption for their particular
stage of life. Children and pregnant and lactating women may
be at increased risk for mercury intoxication from fish
consumption but also are at low risk for CHD. Thus,
avoidance of potentially contaminated fish is a higher priority
for this group. For middle-aged and older men and postmeno-
pausal women, the benefits of fish consumption far outweigh
the risks within the guidelines established by the FDA and
Environmental Protection Agency. Consumption of a wide
variety of species within the guidelines is the best approach to
both minimizing mercury exposure and increasing omega-3
fatty acid intake.
Summary
Omega-3 fatty acids have been shown in epidemiological and
clinical trials to reduce the incidence of CVD. Large-scale
epidemiological studies suggest that individuals at risk for
CHD benefit from the consumption of plant- and marine-
derived omega-3 fatty acids, although the ideal intakes
presently are unclear. Evidence from prospective secondary
prevention studies suggests that EPADHA supplementation
ranging from 0.5 to 1.8 g/d (either as fatty fish or supple-
ments) significantly reduces subsequent cardiac and all-cause
mortality. For -linolenic acid, total intakes of 1.5 to 3 g/d
seem to be beneficial.
Collectively, these data are supportive of the recommen-
dation made by the AHA Dietary Guidelines to include at
least two servings of fish per week (particularly fatty fish). In
addition, the data support inclusion of vegetable oils (eg,
soybean, canola, walnut, flaxseed) and food sources (eg,
walnuts, flaxseeds) high in -linolenic acid in a healthy diet
for the general population (Table 5). The fish recommenda-
tion must be balanced with concerns about environmental
pollutants, in particular PCB and methylmercury, described
in state and federal advisories. Consumption of a variety of
fish is recommended to minimize any potentially adverse
TABLE 4. Risk for Side Effects From Ingestion of Omega-3 Fatty Acids
Gastrointestinal Upset Clinical Bleeding Fishy Aftertaste Worsening Glycemia* Rise in LDL-C†
Up to 1 g/d Very low Very low Low Very low Very low
1 to 3 g/d Moderate Very low Moderate Low Moderate
3 g/d Moderate Low Likely Moderate Likely
*Usually only in patients with impaired glucose tolerance and diabetes.
†Usually only in patients with hypertriglyceridemia.
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achieve desired CVD health outcomes.
RCTs have demonstrated that omega-3 fatty acid supple-
ments can reduce cardiac events (eg, death, nonfatal MI,
nonfatal stroke) and decrease progression of atherosclerosis
in coronary patients. However, additional studies are needed
to confirm and further define the health benefits of omega-3
fatty acid supplements for both primary and secondary
prevention. For example, placebo-controlled, double-blind
RCTs are needed to document both the safety and efficacy of
omega-3 fatty acid supplements in both high-risk patients (eg,
patients with type 2 diabetes, dyslipidemia, and hypertension,
and smokers) and coronary patients on drug therapy. Mech-
anistic studies on their apparent effects on sudden death are
also needed.
A dietary (ie, food-based) approach to increasing omega-3
fatty acid intake is preferable. Still, for patients with coronary
artery disease, the dose of omega-3 (1 g/d) may be greater
than what can readily be achieved through diet alone (Table
5). These individuals, in consultation with their physician,
could consider supplements for CHD risk reduction. Supple-
ments also could be a component of the medical management
of hypertriglyceridemia, a setting in which even larger doses
(2 to 4 g/d) are required (Table 5). The availability of
high-quality omega-3 fatty acid supplements, free of contam-
inants, is an important prerequisite to their extensive use.
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 by on June 5, 2007  circ.ahajournals.org Downloaded from After the publication of the AHA Scientific Statement “Fish Consumption, Fish Oil, Omega-3
Fatty Acids, and Cardiovascular Disease” by Kris-Etherton et al, which appeared in a previous
issue of the journal (Circulation. 2002;106:2747–2757), the following errors were noted in Table
3. First, two other sources for the fatty acid composition of fish should have been included.1,2
Secondly, the footnote to “cod liver oil” should have read, “This intake of cod liver oil would
provide approximately the Recommended Daily Allowance (RDA) of vitamin A and twice the
RDA for vitamin D.” Finally, the EPADHA content for four fish was given incorrectly, and
should have been as follows:
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TABLE 3. Amounts of EPADHA in Fish and Fish Oils and the
Amount of Fish Consumption Required to Provide 1go f
EPADHA per Day
Fish
EPADHA Content,
g/3-oz Serving Fish
(Edible Portion) or g/g Oil
Amount Required to
Provide 1go f
EPADHA per Day,
oz (Fish) or g (Oil)
Sockeye salmon 1.05 2.5 oz
Eastern oysters 0.95 3 oz
Atlantic cod 0.13 23 oz
Pacific cod 0.24 12.5 oz
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